Expert Discusses Real-World Data for Regorafenib in mCRC
Real-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.
Trastuzumab Biosimilar Candidate Shows Promise in Early-Stage Breast Cancer
Francisco J. Esteva, MD, PhD, discusses the current data surrounding CT-P6 demonstrating its potential as a biosimilar for trastuzumab in the United States.